Contributor:

Fact or Fiction: Will Compliance Be an Issue With a Topical Drop for DR?

Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA

Fact or Fiction: Are Integrin Inhibitors a Viable Strategy?

Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA

Fact or Fiction: Can a Topical Formulation Reach the Retina?

Carl D. Regillo, MD, FACS, David A. Eichenbaum, MD, and Anat Loewenstein, MD, MHA

Type 1 Neovascularization or CSC?

Dinah Zur, MD; and Anat Loewenstein, MD, MHA

The Coming Shift in AMD Care

Anat Loewenstein, MD, MHA; and Alistair Laidlaw, MBBS, MD

Gearing Up for a GA Therapy

Kourous A. Rezaei, MD; and Anat Loewenstein, MD, MHA

AI in the Modern Age of Retina

Anat Loewenstein MD, MHA

Home-Based OCT and AMD

Anat Loewenstein, MD

VEGF Inhibition and Beyond: Building on Existing Foundations

Patricio Schlottmann, MD, Anat Loewenstein, MD, Charles C. Wykoff, MD, PhD

Education as In-Person Meetings Are Paused

Anat Loewenstein, MD, John W. Kitchens, MD, Timothy G. Murray, MD, MBA

Management of RVO

Anat Loewenstein, MD

Is There Any Hope for Dry AMD Patients?

Anat Loewenstein, MD, William Tucker, MD